Alimera Sciences Announces Second Quarter 2022 Financial Results
Consolidated Net Product Revenue of $14.6 Million up 36% vs. Second Quarter of 2021U.S. End User Demand up 45% vs....
COVID-19
Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be...
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2022
SALT LAKE CITY, UT , July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --UTMD achieved second calendar quarter (2Q) and first...
Biora Therapeutics to Participate in Upcoming BTIG Investment Conference
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics,...
Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life...
TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a...
AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility
— FDA feedback marks a key milestone in the construction of the facility expected to support AGTC’s pipeline, including the...
Aquestive Therapeutics to Participate in Wedbush PacGrow Healthcare Conference
WARREN, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve...
Virax Biolabs Introduces Monkeypox and Varicella-Zoster Viruses Real-Time PCR Detection Kit
Kits Available in July for DistributionLondon, United Kingdom, July 26, 2022 (GLOBE NEWSWIRE) -- Virax Biolabs Group Limited (“Virax” or...
CinCor Pharma Announces Last Patient Randomized in Phase 2 HALO Trial and Initiation of Long-Term Extension Study for Baxdrostat, a Selective Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension
Open Label Extension Study Will Evaluate Baxdrostat for Up to 52 Weeks Topline Data for Phase 2 HALO Trial Expected...
Simply Better Brands Corp. Announces First Tranche Closing of Private Placement of Common Shares
VANCOUVER, British Columbia, July 26, 2022 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. ("SBBC" or the "Company") (TSX Venture: SBBC,...
U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation
Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE...
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads...
NEXGEL Launches MEDAGEL Hydroliner Pro Pads for Eyelash Protection During Cosmetic Extensions Service
The Company's Proprietary Hydrogel Technology Protects Lower Lashes and Allows for Gentle Removal LANGHORNE, Pa., July 26, 2022 (GLOBE NEWSWIRE)...
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
- At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily), the mean change from baseline...
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies...
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
Completed encouraging Type B meeting with US FDAApplication for EUA planned to be submitted in Q3 2022JENA, Germany, July 26,...
OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven
Collaborators aim to develop and evaluate computation tools, including predictive models for whole genome sequencing-based antibiotic susceptibility testing (wgsAST)Ares plans...
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate...